2009 FDA Pharmaceutical Companies 
pharmaphorum
DECEMBER 28, 2022
In 2018, over 60% of all new molecular entities came from smaller biopharma firms, compared with just over 30% in 2009. So, how do smaller pharmaceutical companies at the cutting edge get ready for their acquisition milestone, so they maximise their value and attractiveness?
Pharmaceutical Technology
OCTOBER 5, 2022
Bringing an end to a 13-year deliberation on a whistleblower lawsuit, Biogen recently agreed to pay a $900 million settlement , amidst increased government alertness on pharmaceutical fraud. In 2009, Tysabri was performing well, having yielded $776 million in sales after being first approved in 2004, as per Biogen’s 2009 financial filings.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Impact Pharmaceutical Services
AUGUST 9, 2022
IMPACT (now part of Syner-G BioPharma Group) has been providing Regulatory Affairs support to a mid-size pharmaceutical company since 2009. Even though this company has a Regulatory Affairs Department, their rapid growth over the years has made “in-sourcing” of help a necessity.
Pharmaceutical Technology
MAY 11, 2008
Pharmaceutical companies, regulatory agencies and governments are becoming increasingly concerned about fraud and counterfeiting throughout the pharmaceutical supply chain, especially with the cost of drugs going up. The pilot scheme for this has been observed by the FDA and EU Commission.
The People's Pharmacy
MAY 8, 2023
Why, then, are FDA inspections abroad so infrequent and disappointing? FDA Inspections Suspended: During the COVID pandemic, the Food and Drug Administration suspended its inspections at most foreign pharmaceutical facilities. Even under the best of conditions, the FDA never inspects all foreign pharmaceutical plants annually.
pharmaphorum
JUNE 6, 2025
Skip to main content Friday 6 June 2025 twitter linkedin facebook rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)
PharmaShots
FEBRUARY 21, 2023
The company's main radiopharma asset includes CycloSam (Samarium-153 DOTMP), a bone-targeting radiopharmaceutical developed by IsoTherapeutics. In Aug’21, the US FDA cleared QSam’s IND application for CycloSam. The company expects to commence P-I clinical trials on metastatic and pediatric primary bone cancer patients.
Expert insights. Personalized for you.
119 
Let's personalize your content